Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shang Yi

Showing results (291-300 of 357) with videos related to

Pageof 36
Sort By:
Journal of Genetics and Genomics = Yi Chuan Xue Bao|August 2, 2021
HPDL deficiency causes a neuromuscular disease by impairing the mitochondrial respirationYu Sun, Xiujuan Wei, Fang Fang, et al.
Annals of Hematology|April 2, 2014
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myelomaShang-Yi Huang, Chung-Wu Lin, Hsiu-Hsia Lin, et al.
Clinical Hematology International|August 11, 2025
Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working GroupWenming Chen, Zhen Cai, Chor Sang Chim, et al.
European Journal of Haematology|July 12, 2024
An open-label, first-in-human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myelomaPrashant Kapoor, Nitya Nathwani, Tomas Jelinek, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|December 26, 2016
A noninterventional observational registry of patients with multiple myeloma treated with lenalidomide in TaiwanShang-Yi Huang, Yuan-Bin Yu, Su-Peng Yeh, et al.
Clinical Hematology International|May 8, 2026
Guidelines and consensus for minimal residual disease-adapted therapy in multiple myeloma from the Pan-Pacific multiple myeloma working groupWenming Chen, Zhen Cai, Chor Sang Chim, et al.
Haematologica|February 1, 2024
Isatuximab-pomalidomide-dexamethasone <i>versus</i> pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysisPaul G Richardson, Aurore Perrot, Jesus San Miguel, et al.
BMC Cancer|May 3, 2015
Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adultsChieh-Lung Cheng, Chi-Cheng Li, Hsin-An Hou, et al.
Mycoses|September 20, 2018
The epidemiology of non-Candida yeast isolated from blood: The Asia Surveillance StudyShang-Yi Lin, Po-Liang Lu, Ban Hock Tan, et al.
Genomics|July 23, 2013
HIVID: an efficient method to detect HBV integration using low coverage sequencingWeiyang Li, Xi Zeng, Nikki P Lee, et al.
Pageof 36

Showing results (291-300 of 357) with videos related to

Sort By:
Pageof 36
Journal of Genetics and Genomics = Yi Chuan Xue Bao|August 2, 2021
HPDL deficiency causes a neuromuscular disease by impairing the mitochondrial respirationYu Sun, Xiujuan Wei, Fang Fang, et al.
Annals of Hematology|April 2, 2014
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myelomaShang-Yi Huang, Chung-Wu Lin, Hsiu-Hsia Lin, et al.
Clinical Hematology International|August 11, 2025
Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working GroupWenming Chen, Zhen Cai, Chor Sang Chim, et al.
European Journal of Haematology|July 12, 2024
An open-label, first-in-human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myelomaPrashant Kapoor, Nitya Nathwani, Tomas Jelinek, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|December 26, 2016
A noninterventional observational registry of patients with multiple myeloma treated with lenalidomide in TaiwanShang-Yi Huang, Yuan-Bin Yu, Su-Peng Yeh, et al.
Clinical Hematology International|May 8, 2026
Guidelines and consensus for minimal residual disease-adapted therapy in multiple myeloma from the Pan-Pacific multiple myeloma working groupWenming Chen, Zhen Cai, Chor Sang Chim, et al.
Haematologica|February 1, 2024
Isatuximab-pomalidomide-dexamethasone <i>versus</i> pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysisPaul G Richardson, Aurore Perrot, Jesus San Miguel, et al.
BMC Cancer|May 3, 2015
Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adultsChieh-Lung Cheng, Chi-Cheng Li, Hsin-An Hou, et al.
Mycoses|September 20, 2018
The epidemiology of non-Candida yeast isolated from blood: The Asia Surveillance StudyShang-Yi Lin, Po-Liang Lu, Ban Hock Tan, et al.
Genomics|July 23, 2013
HIVID: an efficient method to detect HBV integration using low coverage sequencingWeiyang Li, Xi Zeng, Nikki P Lee, et al.
Pageof 36